新型恶唑烷酮类药物DA-7867经静脉或口服给予大鼠后的药代动力学：肠道首过效应
Pharmacokinetics of DA-7867, a new oxazolidinone, after intravenous or oral administration to rats: intestinal first-pass effect.
作者信息
Bae Soo K, Chung Won-Suk, Kim Eun J, Rhee Jae K, Kwon Jong W, Kim Won B, Lee Myung G
机构信息
College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Kwanak-Gu, Seoul 151-742, Korea.
出版信息
Antimicrob Agents Chemother. 2004 Feb;48(2):659-62. doi: 10.1128/AAC.48.2.659-662.2004.
Abstract
Pharmacokinetic parameters of DA-7867 were dose independent after both intravenous administration and oral administration (at doses of 1 to 20 mg/kg of body weight) to rats. After oral administration of DA-7867 to rats at a dose of 10 mg/kg, approximately 8.27% of oral dose was not absorbed from the gastrointestinal tract, F was 70.8%, and approximately 21.8% of the oral dose was eliminated by the intestine (intestinal first-pass effect).
摘要
给大鼠静脉注射和口服（体重剂量为1至20mg/kg）DA - 7867后，其药代动力学参数与剂量无关。以10mg/kg的剂量给大鼠口服DA - 7867后，约8.27%的口服剂量未从胃肠道吸收，F为70.8%，约21.8%的口服剂量被肠道消除（肠道首过效应）。
相似文献
1
Pharmacokinetics of DA-7867, a new oxazolidinone, after intravenous or oral administration to rats: intestinal first-pass effect.
Antimicrob Agents Chemother. 2004 Feb;48(2):659-62. doi: 10.1128/AAC.48.2.659-662.2004.
2
Dose-dependent pharmacokinetics of itraconazole after intravenous or oral administration to rats: intestinal first-pass effect.
Antimicrob Agents Chemother. 2004 May;48(5):1756-62. doi: 10.1128/AAC.48.5.1756-1762.2004.
3
Pharmacokinetics of DA-8159, a new erectogenic, after intravenous and oral administration to rats: hepatic and intestinal first-pass effects.
J Pharm Sci. 2003 Nov;92(11):2185-95. doi: 10.1002/jps.10482.
4
Pharmacokinetics of ipriflavone, an isoflavone derivative, after intravenous and oral administration to rats hepatic and intestinal first-pass effects.
Life Sci. 2002 Feb 1;70(11):1299-315. doi: 10.1016/s0024-3205(01)01508-9.
5
Effects of acute renal failure on the pharmacokinetics of DA-7867, a new oxazolidinone, in rats.
Biopharm Drug Dispos. 2006 Jan;27(1):29-37. doi: 10.1002/bdd.478.
6
Dose-independent pharmacokinetics of metformin in rats: Hepatic and gastrointestinal first-pass effects.
J Pharm Sci. 2006 Nov;95(11):2543-52. doi: 10.1002/jps.20744.
7
Pharmacokinetics of a chemoprotective agent, 2-(allylthio)pyrazine, after intravenous and oral administration to rats: hepatic and gastric first-pass effects.
Drug Metab Dispos. 1999 Feb;27(2):221-6.
8
Excretion and metabolism of DA-7867, a new oxazolidinone, in rats.
Biopharm Drug Dispos. 2005 Mar;26(2):67-75. doi: 10.1002/bdd.434.
9
Effects of protein-calorie malnutrition on the pharmacokinetics of DA-7867, a new oxazolidinone, in rats.
J Pharm Pharmacol. 2004 May;56(5):635-42. doi: 10.1211/0022357023277.
10
Pharmacokinetics of DA-7218, a new oxazolidinone, and its active metabolite, DA-7157, after intravenous and oral administration of DA-7218 and DA-7157 to rats.
J Pharm Pharmacol. 2007 Jul;59(7):955-63. doi: 10.1211/jpp.59.7.0007.
引用本文的文献
1
Potential role of tedizolid phosphate in the treatment of acute bacterial skin infections.
Drug Des Devel Ther. 2013 Apr 3;7:243-65. doi: 10.2147/DDDT.S30728. Print 2013.
2
Therapeutic effect of a novel oxazolidinone, DA-7867, in BALB/c mice infected with Nocardia brasiliensis.
PLoS Negl Trop Dis. 2008 Sep 10;2(9):e289. doi: 10.1371/journal.pntd.0000289.
3
In vitro and in vivo activities of DA-7867, a new oxazolidinone, against aerobic gram-positive bacteria.
Antimicrob Agents Chemother. 2005 Jun;49(6):2498-500. doi: 10.1128/AAC.49.6.2498-2500.2005.
4
Dose-dependent pharmacokinetics of itraconazole after intravenous or oral administration to rats: intestinal first-pass effect.
Antimicrob Agents Chemother. 2004 May;48(5):1756-62. doi: 10.1128/AAC.48.5.1756-1762.2004.
本文引用的文献
1
High-performance liquid chromatographic analysis of DA-7867, a new oxazolidinone, in human plasma and urine and in rat tissue homogenates.
J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Sep 5;794(2):397-403. doi: 10.1016/s1570-0232(03)00476-8.
2
Dose-independent pharmacokinetics of a new reversible proton pump inhibitor, KR-60436, after intravenous and oral administration to rats: gastrointestinal first-pass effect.
J Pharm Sci. 2003 Aug;92(8):1592-603. doi: 10.1002/jps.10427.
3
Dose-independent pharmacokinetics of a candidate for diabetic neuropathy, SR-4668, after intravenous and oral administration to rats: Intestinal first-pass effect.
J Pharm Sci. 2003 May;92(5):1112-24. doi: 10.1002/jps.10376.
4
Dose-independent pharmacokinetics of a new neuroprotective agent for ischemia-reperfusion damage, KR-31543, after intravenous and oral administration to rats: hepatic and intestinal first-pass effects.
J Pharm Sci. 2003 Jan;92(1):190-201. doi: 10.1002/jps.10289.
5
Pharmacokinetics of ipriflavone, an isoflavone derivative, after intravenous and oral administration to rats hepatic and intestinal first-pass effects.
Life Sci. 2002 Feb 1;70(11):1299-315. doi: 10.1016/s0024-3205(01)01508-9.
6
Oxazolidinone antibiotics.
Lancet. 2001 Dec 8;358(9297):1975-82. doi: 10.1016/S0140-6736(01)06964-1.
7
Linezolid: an oxazolidinone antimicrobial agent.
Clin Ther. 2001 Mar;23(3):356-91. doi: 10.1016/s0149-2918(01)80043-6.
8
Gastrointestinal first-pass effect of furosemide in rats.
J Pharm Pharmacol. 2000 Nov;52(11):1337-43. doi: 10.1211/0022357001777487.
9
Intestinal first-pass effect of bumetanide in rats.
Int J Pharm. 2000 Jan 25;194(2):193-9. doi: 10.1016/s0378-5173(99)00360-9.
10
Gastrointestinal first-pass effect of YJA-20379-8, a new reversible proton pump inhibitor, in rats.
J Pharm Pharmacol. 1999 Sep;51(9):1031-6. doi: 10.1211/0022357991773519.
Zotero 插件